Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors

Clinical trial NCT04990726 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04990726
Sponsor: M.D. Anderson Cancer Center
Status: ACTIVE_NOT_RECRUITING
Study type: OBSERVATIONAL

Clinical Stage III Cutaneous Melanoma AJCC v8 Pathologic Stage III Cutaneous Melanoma AJCC v8 Pathologic Stage IIIA Cutaneous Melanoma AJCC v8 Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 Pathologic Stage IIID Cutaneous Melanoma AJCC v8 Melanoma, Stage II Melanoma Stage IV

Start date: 2019-12-05
Primary completion: 2027-02-02
Enrollment: 126

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.